Allschwil, Switzerland, August 21, 2024
Basilea Pharmaceutica Ltd (SIX: BSLN), Allschwil, a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, today announced that continued strong sales performance in Asia Pacific and China for its licensing partner Pfizer's antifungal drug Cresemba® (isavuconazole) has exceeded sales thresholds, resulting in a milestone payment of $1.25 million.
“Achieving our third milestone payment threshold in Asia Pacific and China this year underscores the strong sales performance and growth of Cresemba in the region,” said David Veitch, CEO of Basilea. “We are pleased that Cresemba continues to meet the medical needs of patients suffering from life-threatening invasive mold infections.”
Basilea's license agreement with Pfizer for Cresemva covers 16 countries in Europe (excluding the Nordic countries) and Asia Pacific, as well as China.
Cresemba is approved and sold in more than 70 countries, including the United States, most EU member states, and other countries within and outside Europe. According to the latest market data, total global market sales of Cresemba are expected to reach US$489 million for the 12-month period from April 2023 to March 2024, up 24 percent from the previous year.1
About isavuconazole (Cresemba®)
Isavuconazole is an intravenous (iv) and oral azole antifungal agent marketed under the brand name Cresemba®. Basilea has multiple licensing and distribution agreements for isavuconazole covering approximately 115 countries. In the 27 member states of the European Union, Iceland, Liechtenstein, Norway and the UK, isavuconazole is approved for the treatment of adult patients with invasive aspergillosis and adult patients with mucormycosis when amphotericin B is not appropriate.2 In China, oral and intravenous formulations are approved for the treatment of adult patients with invasive aspergillosis and invasive mucormycosis. Isavuconazole is also approved in the United States and several European countries, including Japan.3 The drug has been granted orphan drug designation for approved indications in the United States, Europe and Australia.
About Basilea
Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative medicines to meet the needs of patients with severe bacterial or fungal infections. We have successfully launched two hospital brands: Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. Additionally, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Visit basilea.com.
Disclaimer
This document contains express or implied forward-looking statements using words such as “believes,” “anticipates,” “expects,” “projects,” “plans,” “may,” “could,” “might” or “will” regarding Basilea Pharmaceutica Ltd, Allschwil and its business, including the progress, timing and completion of research, development and clinical trials of product candidates. Such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, financial situation, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this document as of this date and undertakes no obligation to update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise.
For further information, please contact:
This press release can be downloaded at www.basilea.com.
References
IQVIA Analytics Link, March 2024. Market sales are reported as annualized moving total (MAT) in USD. European Public Assessment Report (EPAR) Cresemba: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba (Accessed: 20 August 2024) Registration status and approved indications may vary by country.
